Zhang Sainan, Yang Ya, Fan Linxiao, Zhang Fen, Li Lanjuan
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Ann Transl Med. 2020 Apr;8(8):565. doi: 10.21037/atm.2020.03.218.
Liver disease is a major health issue which present poor clinical treatment performance. Cirrhosis and liver failure are common clinical manifestations of liver diseases. Liver transplantation is recognized as the ultimate and most efficient therapy to the end stage of liver disease. But it was limited by the shortage of honor organs and high cost. Nowadays, stem cell therapy gained more and more attention due to its attractive efficacy in treating liver disease especially in cirrhosis during the clinical trials. Mesenchymal stem cell (MSC) can be differentiated into hepatocytes, promote liver regeneration, inhibit liver fibrosis and induce liver apoptosis, particularly via paracrine mechanisms. This review will highlight recent clinical applications of MSC, providing the available evidence and discussing some unsolved questions in treating liver disease.
肝脏疾病是一个主要的健康问题，其临床治疗效果不佳。肝硬化和肝衰竭是肝脏疾病常见的临床表现。肝移植被认为是终末期肝脏疾病的最终且最有效的治疗方法。但它受到供体器官短缺和高成本的限制。如今，干细胞疗法因其在治疗肝脏疾病尤其是临床试验中的肝硬化方面具有诱人的疗效而越来越受到关注。间充质干细胞（MSC）可分化为肝细胞，促进肝脏再生，抑制肝纤维化并诱导肝脏细胞凋亡，特别是通过旁分泌机制。本综述将重点介绍MSC最近的临床应用，提供现有证据并讨论在治疗肝脏疾病中一些尚未解决的问题。
